FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Endocrinology Advisor1d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
Interesting Engineering on MSN2d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
PharmiWeb2d
Injectable Drug Delivery Market Set for Significant Growth, Projected to Reach USD 113.87 Billion by 2034 at a 8.70% of CAGR
Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in 2024, with strong growth expectations due to advancements in healthcare, ...
PharmiWeb3d
Insulin Delivery Devices Market Size & Share | Growth Analysis 2035
The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...